2/77

JAN 1 0 2003

CERTIFICATE OF MAILING

here Critify that this correspondence is being deposited with the United States Postal Service as First Class Mail to:

on 6 January 2003.

Athryn Marley

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Michael G. Kahn et al.

Application No.: 09/970,182

Confirm. No.: 9764

Filed: 3 October 2001

Title: TIMELINE FORECASTING FOR

CLINICAL TRIALS

Group Art Unit: 2177

Examiner: Unknown

Customer No. 22470

RECEIVED

Attorney Docket No.: FSTK 100a

JAN 1 3 2003

Technology Center 2100

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Assistant Commissioner for Patents Washington, DC 20231

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56.

Enclosed is a Form PTO-1449 and a copy of each cited document as required by 37 C.F.R. 1.98. The Examiner is requested to initial the Form PTO-1449 and return it to the undersigned in accordance with M.P.E.P. 609.

This statement qualifies under 37 C.F.R. 1.97, subsection (b) because it is being filed before the mailing date of the first Office Action on the merits

<u>Fee Authorization</u>. The Commissioner is hereby authorized to charge underpayment of any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-0869 (FSTK 1002-0). A duplicate copy of this authorization is enclosed.

Respectfully submitted,

HAYNES BEFFEL & WOLFELD LLP

Date:

1/6/2003

Warran S. Wolfeld Pag No. 21

HAYNES BEFFEL & WOLFELD LLP

P.O. Box 366

Half Moon Bay, CA 94019 Telephone: (650) 712-0340 Facsimile: (650) 712-0263

Please type a plus sigc (+) inside this box →	+
---	---

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 09/970,182

Filing Date 3 October 2001

First Named Inventor Michael G. Kahn

Group Art Unit 2177

Examiner Name Unknown

Complete if Known

Description:

Application Number 09/970,182

FIGURE 19/970,182

FIRST Name 19/970,182

Application Number 19/970,182

Application Number 19/970,182

Filing Date 3 October 2001

FIGURE 19/970,182

FILING 19/970,182

Attorney Docket Number FSTK 1002-0 Technology Center 2100

				U.S. PATENT DOCU	JMENTS	
Examiner Initials*	Cite No.1	U.S. Patent Number	Kind Code ² (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	6,108,63	35	Herren et al.	08-22-2000	
	A2	6,188,98	38	Barry et al.	02-13-2001	
	A 3					
	A4					
	A5					
	A6					
	A7					
	A8					
	A9					-
	A10					
	A11					
	A12					
	A13					
	A14					
	A15					
	A16					
	A17					
	A18					
	A19					
	A20					

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docur Number ⁴	nent Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
	B1		WO 99/63473		Phase Forward, Inc.	12-09-1999		
	B2							
	B3		-					
	B4							
	B5							
	B6							
	B7							
	B8				· 			
	B9		•					
	B10							

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please	type a	plus	sign	(+)	inside	this	box	\rightarrow	+

PTO/SB/08B (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449B/PT	n	. <u>-</u>	Complete if Known				
				Application Number	09/970,182	DE050/		
INFC	PRMATION	N DIS	CLOSURE	Filing Date	3 October 2001	RECEIV	ヒレ	
STATEMENT BY APPLICANT		First Named Inventor	Michael G. Kahr					
•				Group Art Unit	2177	JAN 1 3 2	003	
	(use as many s	sheets as	necessary)	Examiner Name	Unknown		ĺ	
Sheet	2	of	2	Attorney Docket Number	FSTK 1002-0	Technology Cent	er 2100	

Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. A. ADVANI, S. TU, and M. MUSEN, "Domain Modeling with Integrated Ontologies: Principles	T²
C1		
	for Reconciliation and Reuse," SMI Report No. SMI-97-0681 (1997).	
C2	Domain Pharma Corporation, "Clintrial 4," Release 4.2 (Brochure) (1999).	
С3	http://smi-web.stanford.edu/pubs/SMI_Abstracts/SMI-1999-0801.html, visited on 01/01/2000.	
C4		
C5	(1998).	
C6	M. MUSEN, S. TU, A. DAS, and Y. SHAHAR, "EON: A Component/Based Approach to Automation of Protocol-Directed Therapy," SMI Report No. SMI-96-0606, JAMIA 3:367-388 (1996).	
C7	L. OHNO-MACHADO, et al., "The GuideLine Interchange Format: A Model for Representing Guidelines," Journal of the American Medical Informatics Association 5(4): 357-372 (1998).	
C8	Phase Forward, Incorporated, Products Overview, web page, available at http://www.phaseforward.com/products/products_content.htm (visited 4/26/2000).	
С9	S. WOOLLEN, "Computerized Systems Used in Clinical Trials," Slides for ACRP Annual Meeting, May 27, 1999.	
C10	DOUGLAS B. FRIDSMA, M.D., et al., "Representing Medical Protocols for Organizational Simulation: An Information Processing Approach," J. Computational & Mathematical Org. Theory" 4(1):71-95 (1998)	
C11	MICHAEL G. KAHN, et al. U.S. Patent Application No. 09/584,936 filed May 31, 2000.	
	C4 C5 C6 C7 C8 C9 C10	Protégé-2000)," SMI Report Number SMI-1999-0801 (1999), available at http://smi-web.stanford.edu/pubs/SMI_Abstracts/SMI-1999-0801.html, visited on 01/01/2000. IKnowMed, Physician Solutions, web page screen shorts (2 pp.), available at http://www.knowmed.com/solutions_advanced.html (visited 4/20/2000). M. MUSEN, "Domain Ontologies in Software Engineering: Use of Protégé with the EON Architecture," Methods of Information in Medicine 37: 540-550, SMI Report No. SMI-97-0657 (1998). M. MUSEN, S. TU, A. DAS, and Y. SHAHAR, "EON: A Component/Based Approach to Automation of Protocol-Directed Therapy," SMI Report No. SMI-96-0606, JAMIA 3:367-388 (1996). C. OHNO-MACHADO, et al., "The GuideLine Interchange Format: A Model for Representing Guidelines," Journal of the American Medical Informatics Association 5(4): 357-372 (1998). Phase Forward, Incorporated, Products Overview, web page, available at http://www.phaseforward.com/products/products_content.htm (visited 4/26/2000). S. WOOLLEN, "Computerized Systems Used in Clinical Trials," Slides for ACRP Annual Meeting, May 27, 1999. DOUGLAS B. FRIDSMA, M.D., et al., "Representing Medical Protocols for Organizational Simulation: An Information Processing Approach," J. Computational & Mathematical Org. Theory" 4(1):71-95 (1998) MICHAEL G. KAHN, et al. U.S. Patent Application No. 09/584-936 filed May 31, 2000.

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.